Valuation dashboard for InflaRx N.V. (IFRX) with P/E N/A, P/B 1.38, EV/EBITDA -3.32 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases.
Analysis Summary
Trailing-twelve-month margins: gross margin 482.0%, operating margin 3622.7%, net margin 3875.3%.
At the current price of $2.04, IFRX has negative trailing earnings (P/E not meaningful) and an ROE of -58.00%. Market capitalisation stands at $300M.
Balance sheet quality for IFRX: current ratio of 4.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.38 |
| EV / EBITDA | -3.32 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.20 |
| vs Current Price | -90.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IFRX | InflaRx N.V. | $300M | 1.38 | -58.0% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.04 |
| Market Cap | $300M |
| Exchange | NASDAQ |
| Country | DE |
Profitability
| Return on Equity | -58.00% |
| Return on Invested Capital | -24.89% |
| Return on Assets | -23.46% |
| Gross Margin | 48201.61% |
| Operating Margin | 362271.47% |
| Net Margin | 387532.08% |
Related companies: ARTV · ATYR · CNTB · CNTX · IMA · KLRS · MGX
Explore sector: Healthcare · Biotechnology
More sections of IFRX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks